Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Shockwave Medical (SWAV – Research Report), Amarin (AMRN – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report).
Shockwave Medical (SWAV)
In a report issued on January 10, Mike Kratky from Leerink Partners maintained a Buy rating on Shockwave Medical. The company’s shares closed last Friday at $216.16.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
Shockwave Medical has an analyst consensus of Moderate Buy, with a price target consensus of $233.89, representing an 8.2% upside. In a report issued on January 12, Piper Sandler also reiterated a Buy rating on the stock with a $275.00 price target.
See the top stocks recommended by analysts >>
Amarin (AMRN)
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Amarin on January 10. The company’s shares closed last Friday at $1.18.
According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Amarin with a $1.00 average price target.
Mereo Biopharma Group Plc (MREO)
In a report issued on January 10, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Mereo Biopharma Group Plc. The company’s shares closed last Friday at $2.95, close to its 52-week high of $3.08.
According to TipRanks.com, Schwartz has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Mereo Biopharma Group Plc is a Strong Buy with an average price target of $4.50, representing a 55.2% upside. In a report issued on January 8, Needham also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SWAV:
- Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
- Oppenheimer says Aetna’s PAD prior authorization spills over to Humana
- Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- ShockWave Medical price target lowered to $223 from $284 at Morgan Stanley
- Needham medtech analysts hold analyst/industry conference call
